07:00 , Mar 18, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Not applicable In vitro and chick embryo studies identified light-activated boron dipyrromethene compounds that could help...
08:00 , Mar 8, 2010 |  BC Week In Review  |  Clinical News

Aptocine talaporfin sodium: Completed Phase III enrollment

Light Sciences completed enrollment of 450 patients in an open-label, international Phase III trial comparing Aptocine plus chemotherapy vs. chemotherapy alone. The company also said the occurrence of 198 progression events has triggered the first...
07:00 , Aug 24, 2009 |  BC Week In Review  |  Clinical News

Aptocine talaporfin sodium: Phase II started

Light Sciences began a single-arm, open-label, Australian and New Zealand Phase II trial to evaluate 1 mg/kg IV Aptocine followed by 100 J/cm of light delivered for 83 minutes in 40 patients. Light Sciences Oncology...
07:00 , Aug 17, 2009 |  BC Week In Review  |  Clinical News

Aptocine talaporfin sodium: Phase I started

Light Sciences began a single-arm, open-label, U.S. Phase I trial to evaluate 2 dosages of IV Aptocine using 50, 100, 150 or 200 J/cm of light in 18-24 patients ages 18-34 with PN tumors that...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Clinical News

Litx: Completed Phase III enrollment

Light Sciences completed enrollment of 200 patients in an open-label, international Phase III trial comparing Litx to standard of care treatments including radiofrequency ablation (RFA), transarterial chemoembolization (TACE) and percutaneous ethanol injection (PEI). Light Sciences...
07:00 , Jul 21, 2008 |  BioCentury  |  Finance

Ebb & Flow

In the largest untranched biotech financing this year, genome sequencing company Pacific Biosciences (formerly Nanofluidics) raised $100 million last week in a series E round. The company now has raised $178 million since it was...
00:28 , Jul 16, 2008 |  BC Extra  |  Financial News

Light Sciences raises $40.1 million

Light Sciences Oncology (Bellevue, Wash.) raised $40.1 million in a series C round. Investors were not disclosed. Leerink acted as placement agent and financial advisor. Light Sciences is developing Light Infusion Therapy ( Litx), a...
07:00 , Jul 14, 2008 |  BC Week In Review  |  Clinical News

Litx: Phase IIa start

This quarter, Light Sciences will begin an Australian Phase IIa trial in 40 patients. Light Sciences Oncology Inc., Bellevue, Wash.   Product: Litx   Business: Genitourinary   Molecular target: Not available   Description: Photodynamic therapy using talaporfin (LS11)...
07:00 , Jul 14, 2008 |  BC Week In Review  |  Clinical News

Litx: Phase I/II start

This quarter, Light Sciences will begin a dose-escalation, U.S. Phase I/II trial in 12 patients. Light Sciences Oncology Inc., Bellevue, Wash.   Product: Litx   Business: Genitourinary   Molecular target: Not available   Description: Photodynamic therapy using talaporfin...
07:00 , May 26, 2008 |  BioCentury  |  Finance

Ebb & Flow

Based on its track record of exits from its BioDiscovery 1 and 2 funds during the last eight years, Edmond de Rothschild Investment Partners has raised a new E150 million ($233.8 million) fund in less...